A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00241007
- Lead Sponsor
- Novartis
- Brief Summary
SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 836
Inclusion Criteria
SUCCESSFUL COMPLETION OF STUDY CVAH631C2301
Exclusion Criteria
- NONE
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Adverse events and serious adverse events at each study visit for 54 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure from baseline after 54 weeks Change from baseline in systolic blood pressure from baseline after 54 weeks Change from baseline in standing diastolic and systolic blood pressure after 54 weeks Hematology and blood chemistries up to 54 weeks Physical condition including pregnancy, pulse and weight at each study visit
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States